SQI DIAGNOSTICS Receives FDA Clearance for its Ig_plex Celiac DGP Panel for Sale in the United States
PR Newswire - Thu Nov 13, 2:52PM CST
SQI Diagnostics Inc. (the "Company" or "SQI Diagnostics"
SQD.VN: 0.375 (+0.025)
SQI Diagnostics to Present at the 15th Annual Immunogenicity for Biotherapeutics Conference
PR Newswire - Thu Nov 13, 2:13PM CST
SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: SQIDF), a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that it will present at the Immunogenicity for Biotherapeutics Conference on Tuesday, October 21, 2014 in Boston, Massachusetts.
SQD.VN: 0.375 (+0.025)
IIROC Trade Resumption - SQI Diagnostics Inc.
Newsfile Corp - Mon Nov 10, 7:19AM CST
Trading resumes in:
IIROC Trade Halt - SQI Diagnostics Inc.
Newsfile Corp - Fri Nov 07, 2:23PM CST
The following issues have been halted by IIROC:
SQI Diagnostics Announces New Chairman of Board of Directors
PR Newswire - Mon Sep 29, 8:05AM CDT
SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: SQIDF), a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, is pleased to announce the appointment of Peter Winkley to Chairman of the Board of Directors of SQI, replacing Claude Ricks. Mr. Ricks will continue to serve as a Director on the Board and will continue to provide leadership to the Company.
SQD.VN: 0.375 (+0.025)
SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States
CNW Group - Wed Sep 17, 8:05AM CDT
SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: SQIDF), a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that its common shares have been approved for trading in the United States on the OTCQX marketplace ("OTCQX"
SQD.VN: 0.375 (+0.025)
OTC Markets Group Welcomes SQI Diagnostics to OTCQX®
PR Newswire - Wed Sep 17, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: SQIDF), a life sciences and diagnostics company, has qualified to trade on OTCQX®, the best marketplace.
SQD.VN: 0.375 (+0.025)
SQI Diagnostics Contracted to Automate Pathogen Detection Assays
PR Newswire - Fri Aug 22, 7:30AM CDT
SQI Diagnostics Inc. (TSX-V: SQD), a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that it has entered into a Master Service Agreement to contract with a UK-based company to automate their DNA-based pathogen detection assays. During the initial phase of this agreement, SQI will be paid to deliver an automated working prototype of one of the customer's assays, operational on SQI's sqidlite(TM) system. The initial phase is scheduled for completion by mid-September 2014. It is anticipated that other molecular diagnostic tests will be commissioned in a separate agreement following successful implementation of the initial phase.
SQD.VN: 0.375 (+0.025)
SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost
PR Newswire - Mon Aug 18, 5:58PM CDT
Management to comment on SQI's commercial progress and opportunities -
SQD.VN: 0.375 (+0.025)
SQI Diagnostics Reports Fiscal Third Quarter Results
PR Newswire - Wed Aug 06, 8:25AM CDT
Commercialization Progress Continues with Global Pharmaceutical Companies -
SQD.VN: 0.375 (+0.025)
SQI Diagnostics Appoints Industry Veteran to its Board of Directors
PR Newswire - Tue Jul 15, 1:15PM CDT
Addition of Dr. Allan Pronovost Strengthens US Commercialization Strategy -
SQD.VN: 0.375 (+0.025)
SQI Diagnostics Signs Commercial Agreement with Global Pharma Customer
PR Newswire - Thu Mar 20, 2:26PM CDT
SQI to Develop Custom 21-Plex Protein Microarray for Drug Epitope Mapping -
SQD.VN: 0.375 (+0.025), OSUR: 8.77 (-0.19)
SQI Diagnostics Reports Third Quarter Financial Results
Business Wire - Mon Aug 26, 7:00AM CDT
SQI Diagnostics Inc. (TSX-V: SQD), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced its financial and operational results for the third quarter-ended June 30, 2013.
SQD.VN: 0.375 (+0.025)
SQI Diagnostics Provides Update on Commercial Milestones with Multiple Global Pharma Projects
Business Wire - Tue Jul 30, 7:00AM CDT
SQI Diagnostics Inc. (TSX-V: SQD), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today provided an update on the significant progress on its projects with two global pharmaceutical companies previously announced on May 21, 2013. The names of the global pharmaceutical companies have been omitted owing to confidentiality agreements with both of the entities and SQI Diagnostics.
SQD.VN: 0.375 (+0.025)